ArticleInternational journal of clinical oncology2026
Association between response to gemcitabine-based neoadjuvant therapy and efficacy of gemcitabine plus nab-paclitaxel for recurrent pancreatic ductal adenocarcinoma.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGemcitabine-based neoadjuvant therapy is frequently employed to enable curative resection of pancreatic ductal adenocarcinoma. Gemcitabine plus nab-paclitaxel (GnP) is often given to patients who relapse post-resection, resulting in multiple courses of gemcitabine-containing treatment regimens. However, the effect of prior gemcitabine-based neoadjuvant therapy on the efficacy of GnP therapy remains unclear. This study aimed to determine whether prior gemcitabine-based neoadjuvant therapy affects the therapeutic outcomes of GnP in patients with recurrent pancreatic ductal adenocarcinoma following curative resection.
methodsWe retrospectively analyzed 51 patients with resectable and borderline resectable pancreatic ductal adenocarcinoma who received gemcitabine-based neoadjuvant chemoradiotherapy, underwent curative-intent surgery, and were treated with GnP post-recurrence. Patients were divided into high-regression (≥ 30% reduction in tumor diameter; 32 patients) and low-regression (< 30%; 19 patients) groups based on the tumor reduction rate during neoadjuvant therapy.
resultsMultivariate analysis identified tumor regression and the time from surgery to recurrence as independent prognostic factors for progression-free survival of GnP therapy following recurrence. Median progression-free survival was significantly longer in the high-regression group (11.8 vs. 5.8 months, p = 0.010). The objective response rate to GnP was significantly higher in the high-regression than low-regression groups (43.8% vs. 10.5%; p = 0.015).
conclusionsPatients with greater tumor regression during gemcitabine-based neoadjuvant therapy had better progression-free survival and treatment response to GnP therapy following recurrence. These findings suggest that treatment response to neoadjuvant therapy correlates with post-recurrence outcomes and contributes to the advancement of treatment strategies for recurrent pancreatic ductal adenocarcinoma.
Indexed as
Identifiers
42400776What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.